New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 16, 2012
10:07 EDTALKS, AMTD, AGN, CHMT, ETFC, SCHW, VAROn The Fly: Analysts Initiation Summary
Today's noteworthy initiations include: Allergan (AGN) initiated with a Buy at SunTrust...Varian Medical (VAR) initiated with a Buy at Benchmark Co. and with a Buy at SunTrust...E-Trade (ETFC) initiated with a Neutral at Compass Point...TD Ameritrade (AMTD) initiated with a Neutral at Compass Point...Charles Schwab (SCHW) initiated with a Neutral at Compass Point...Chemtura (CHMT) initiated with a Buy at KeyBanc...Alkermes (ALKS) initiated with a Buy at Mizuho.
News For AGN;VAR;ETFC;AMTD;SCHW;CHMT;ALKS From The Last 14 Days
Check below for free stories on AGN;VAR;ETFC;AMTD;SCHW;CHMT;ALKS the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
April 9, 2014
10:06 EDTETFCOn The Fly: Analyst Upgrade Summary
AmSurg (AMSG) upgraded to Buy from Hold at Cantor... CBOE Holdings (CBOE) upgraded to Buy from Neutral at BofA/Merrill... Carlyle Group (CG) upgraded to Outperform from Perform at Oppenheimer... FireEye (FEYE) upgraded to Buy from Hold at Topeka... Fortune Brands (FBHS) upgraded to Outperform from Neutral at Credit Suisse... Gray Television (GTN) upgraded to Outperform from Market Perform at Wells Fargo... Hibbett Sports (HIBB) upgraded to Overweight from Neutral at Piper Jaffray... LinkedIn (LNKD) upgraded to Buy from Hold at Topeka... Mallinckrodt (MNK) upgraded to Buy from Neutral at UBS... NXP Semiconductors (NXPI) upgraded to Strong Buy from Outperform at Raymond James... Nexstar (NXST) upgraded to Outperform from Market Perform at Wells Fargo... Penn National (PENN) upgraded to Overweight from Equalweight at Barclays... Philip Morris (PM) upgraded to Neutral from Reduce at Nomura... SAIC (SAIC) upgraded to Market Perform from Underperform at Wells Fargo... Sinclair Broadcast (SBGI) upgraded to Outperform from Market Perform at Wells Fargo... Yelp (YELP) upgraded to Buy from Fair Value at CRT Capital... Danaher (DHR) upgraded to Strong Buy from Buy at ISI Group... Quanex (NX) upgraded at BB&T... Omnicell (OMCL) upgraded at Craig-Hallum... Volkswagen (VLKAY) upgraded to Outperform from Market Perform at Bernstein... Magna (MGA) upgraded to Neutral from Sell at Citigroup... Actavis (ACT) upgraded to Positive from Neutral at Susquehanna... E-Trade (ETFC) upgraded to Neutral from Underperform at BofA/Merrill... AmerisourceBergen (ABC) upgraded to Outperform from Market Perform at FBR Capital... CONSOL (CNX) upgraded to Outperform from Neutral at Macquarie.
09:11 EDTETFCOn The Fly: Pre-market Movers
Subscribe for More Information
07:49 EDTALKSAlkermes price target raised to $66 from $60 at Leerink
Subscribe for More Information
07:28 EDTETFCE-Trade upgraded to Neutral from Underperform at BofA/Merrill
Subscribe for More Information
April 8, 2014
14:43 EDTALKSAlkermes price target rasied to $66 from $60 at Leerink
11:22 EDTETFCOptions with increasing implied volatility: CYTK NSR NOW ETFC SPLK
Subscribe for More Information
09:00 EDTALKSAlkermes rises 7.4%
Alkermes is up 7.4%, or $3.03, to $44.13
07:47 EDTALKSAlkermes to host conference call
Subscribe for More Information
07:04 EDTALKSAlkermes announces phase 3 'positive' results from aripiprazole lauroxil study
Alkermes announced "positive" topline results from a randomized, double-blind, placebo-controlled phase 3 clinical trial of aripiprazole lauroxil in patients with schizophrenia. Patients treated once monthly with either 441 mg or 882 mg of aripiprazole lauroxil demonstrated statistically significant reductions from baseline in Positive and Negative Syndrome Scale total scores at week 12, compared to placebo, which was the prespecified primary endpoint in the study. Based on the positive results from this phase 3 study, Alkermes plans to submit a New Drug Application to the U.S. Food and Drug Administration in 3Q14. In addition to meeting the prespecified primary efficacy endpoint, the study also met the prespecified key secondary endpoint of improvement on the Clinical Global Impression-Improvement scale versus placebo at week 12. Aripiprazole lauroxil was generally well tolerated in the phase 3 study, and the safety profile of aripiprazole lauroxil was similar to that reported with oral aripiprazole. The most common adverse events in the study were insomnia, akathisia and headache. Alkermes will present data from the phase 3 study at an upcoming medical meeting and submit the results for publication in a peer-reviewed journal.
April 7, 2014
12:01 EDTETFCStocks with call strike movement; ETFC PCLN
Subscribe for More Information
11:37 EDTETFCOptions with increasing implied volatility: CYTK NSR NOW ETFC LF
Subscribe for More Information
05:49 EDTETFCStocks with implied volatility movement; ETFC PCLN
Subscribe for More Information
April 4, 2014
17:12 EDTETFC, SCHW, AMTDMarket finishes mixed as Nasdaq sells off into weekend
Subscribe for More Information
14:55 EDTSCHWCharles Schwab April and May volatility increases to 28 on price movement
Subscribe for More Information
14:52 EDTAMTDTD Ameritrade April volatility increases on wide price movement
Subscribe for More Information
14:48 EDTETFCE-Trade volatility increases as shares pull back
E-Trade April call option implied volatility is at 51, May is at 48, July is at 39; compared its 26-week average of 33 according to Track Data, suggesting large price movement amid concerns that regulators will look to eliminate one of the companies' more profitable businesses.
12:09 EDTAMTD, ETFCOn The Fly: Midday Wrap
Subscribe for More Information
10:39 EDTAMTD, ETFCE-Trade, TD Ameritrade continue sell-off amid concerns
Subscribe for More Information
09:09 EDTAMTD, ETFCE-Trade, TD Ameritrade reflect high chance of end to payments, says Sterne Agee
Subscribe for More Information
07:36 EDTSCHW, AMTD, ETFCE-brokers decline 'seems excessive,' says Wells Fargo
Wells Fargo believes that the decline in e-brokers E*TRADE Financial Corp.(ETFC), TD Ameritrade Holding Corp.(AMTD), and Charles Schwab Corporation (SCHW) "seems excessive." The firm believes the weakness was caused by concerns that the companies' payment for order flow, or PFOF, could be curtailed in the wake of the controversy over high frequency trading. Wells thinks these concerns are premature, as more data would be needed before PFOF could be banned. Wells keeps an Outperform rating on TD Ameritrade, and Market Perform ratings on Ameritrade and Charles Schwab.
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use